Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...
Read MoreMasitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...
Read MoreCerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreFor one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...
Read MoreIn an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read More
Only a few weeks prior to MSVirtual2020, the fully human anti-CD20 monoclonal antibody ofatumumab...
Read More
Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...
Read More
Most patients with metastatic urothelial cancer respond to first-line chemotherapy but relapse...
Read More
Both CheckMate-649 and ATTRACTION-4 showed a statistically significant improvement in...
Read More
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...
Read More
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....
Read More
While many patients with hormone receptor (HR)-positive and human epidermal growth factor receptor...
Read More
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant...
Read More
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. The phase 3...
Read More
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...
Read More
No standard treatment has been defined yet for second- or third-line systemic treatment of...
Read More
According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...
Read More
Addition to chemotherapy may set a new Standard Immunotherapy for patients with high-risk gastric...
Read More
The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...
Read MoreThank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do? 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for...
Read More
